The evaluation of the efficacy and safety of Hainosankyuto on purulence in patients with lymphedema
Not Applicable
- Conditions
- Patients with lymphedema
- Registration Number
- JPRN-UMIN000013590
- Lead Sponsor
- Hokkaido University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with aldosteronism, myopathy and hypokalemia 2)Patients who were prescribed Kampo medicine within 4 weeks before entry 3)Patients who were prescribed an adrenocortical hormonic agent or an anti-allergic agent 4)Patients with serious complications (liver, kidney, heart, blood, or metabolic disorders) 5)Patients with recurrent or metastasized cancer 6)Pregnant patients, breast-feeding patients or patients hoping to become pregnant 7)Patients considered inappropriate by the study investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of days to clear the symptoms of purulence
- Secondary Outcome Measures
Name Time Method 1)The severity of the symptoms of purulence 2)The body temperature 3)QOL questionnaire 4)The circumference of the region of lymphedema (the affected side) 5)Immunologic test [Measuring NK cell activity, balance between Th1 and Th2, and cytokine (TNF-alpha, IL-12)]